PaxVax, Inc. Acquires FDA-Approved Typhoid Vaccine Vivotif
7/28/2014 8:54:00 AM
REDWOOD CITY, Calif.--(BUSINESS WIRE)--PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that it has acquired the oral typhoid vaccine Vivotif® from Crucell Switzerland AG, as well as its manufacturing facility in Thörishaus, near Bern, Switzerland. Additionally, PaxVax is acquiring marketing, sales and distribution capabilities in select markets including the United States, and certain other assets related to travel vaccines such as hepatitis A. Financial terms of the transaction were not disclosed.
Help employers find you! Check out all the jobs and post your resume.
comments powered by